The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,292,064 | -613,174 | -4,801,149 | -7,649,189 |
| Stock-based compensation | 146,714 | 148,360 | 152,421 | 318,193 |
| Franchise tax payable | - | 0 | 0 | -4,134 |
| Change in fair value of derivative liabilities | 108,627 | -28,850 | 67,039 | - |
| Income tax payables | - | 0 | 0 | -50 |
| Prepaid expenses and other receivables | -62,879 | -104,228 | 232,968 | -559,928 |
| Accounts payable - related party | -539,834 | 549,150 | -2,523 | 3,719 |
| Other payables and accrued liabilities | -59,332 | 162,799 | -35,152 | -90,993 |
| Accrued liability - related party | -4,125,000 | -500,000 | 4,125,000 | 5,981,666 |
| Net cash used in operating activities | -6,698,010 | -177,487 | -727,332 | -880,860 |
| Payments of transactions cost | 758,882 | 64,821 | 12,652 | 40,000 |
| Proceeds received from issuance of common stock, prefunded warrants and common stock warrants for registered direct offering | 7,999,988 | 0 | 1,050,000 | 1,350,000 |
| Purchase of treasury stock | - | 0 | 0 | 29,462 |
| Proceeds received from exercise of prefunded warrants | 6 | - | - | - |
| Net cash provided by (used in) financing activities | 7,241,112 | -64,821 | 1,037,348 | 1,280,538 |
| Net change in cash | 543,102 | -242,308 | 310,016 | 399,678 |
| Cash at beginning of the period | 1,384,302 | 1,626,610 | 916,916 | - |
| Cash at end of the period | 1,927,404 | 1,384,302 | 1,626,610 | - |
Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. (ESLA)